The JN.1 variant has become dominant in Australia and around the world, causing large waves of infections. Here’s what we know about it so far – and why it’s so important.
With the emergency phase of the COVID-19 pandemic in the rearview mirror, at least for now, we look back on a handful of stories that provided sharp insights at key moments in the pandemic.
Many questions remain about next steps for US vaccine policy. But the FDA advisory panel’s hearty endorsement of a single-composition COVID-19 vaccine represents a pivotal step.
Reports from China indicate BF.7 is quicker to transmit and has greater capacity to escape prior immunity than other omicron subvariants. But we shouldn’t be alarmed at this stage.
New Zealand’s proportion of reinfections is now at 17% of new cases. As new variants continue to proliferate, vaccine boosters would protect those most vulnerable and reduce the risk of long COVID.
Case numbers are falling in all age groups, including over-70s. This is good news as case rates in older people have been a key driver of the steep rise in hospitalisations and deaths in this wave.
We published an article earlier this month that contained incorrect estimates for the basic reproduction number (R0) for COVID subvariants BA.4/BA.5 and BA.2. We have now corrected the error, but I wanted…
According to a letter from Biden’s doctor, the president has a runny nose, mild fatigue and a slight cough. The letter also noted that Biden began taking an antiviral drug the morning he tested positive.